Home Search Abstracts Browse Oral Sessions Browse Poster Sessions
Session 169  Poster Abstracts
Hepatitis B Co-infection
Monday, 1-4 pm
Room: Hall B
    1028 The Epidemiology of Hepatitis B Virus Infection in HIV-1-infected Individuals over 20 Years: The Effect of HAART and Vaccination
H Chun1,2, A Fieberg3,4, K Huppler Hullsiek3,4, N Crum-Cianflone2,4, W Bradley4, A Ganesan4,5, A Weintrob4,6, Robert Barthel*7, and M Landrum4,8
1Naval Hlth Res Ctr, San Diego, CA, US; 2Naval Med Ctr San Diego, CA, US; 3Univ of Minnesota, Minneapolis, US; 4Infectious Disease Clinical Res Prgm, Bethesda, MD, US; 5Natl Naval Med Ctr, Bethesda, MD, US; 6Walter Reed Army Med Ctr, Washington, DC, US; 7Naval Med Ctr Portsmouth, VA, US; and 8San Antonio Med Ctr, Fort Sam Houston, TX, US
    1029 Death, HIV Suppression, and CD4 Recovery among HIV/HBV-co-infected Men Receiving ART: MACS
Christopher Hoffmann*1, E Seaberg2, K D'Acunto3, M Witt4, J Phair5, and C Thio1
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 3Univ of Pittsburgh Sch of Publ Hlth, PA, US; 4David Geffen Sch of Med, Univ of California, Los Angeles, US; and 5Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US
    1030 Chronic HBV/HIV Co-infection and HIV Suppression, CD4 Recovery, Mortality, and Hepatotoxicity in an African ART Cohort
Christopher Hoffmann*1, S Charalambous2, D Martin3, K Fielding4, A Moss3, G Churchyard2, R Chaisson1, A Grant4, and C Thio1
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2Aurum Inst for Hlth Res; 3Toga Labs, Zambia; and 4London Sch of Hygiene and Tropical Med, UK
    1031 Effect of HBV DNA Levels on HIV Infection and Response to ART in a HIV/HBV-co-infected Nigerian Cohort
J Idoko1, S Meloni2, M Muazu1, C Hawkins3, B Badung1, N Ladep4, P Kanki2, R Murphy3, E Ekong5, and Chloe Thio*6
1Jos Univ Teaching Hosp, Plateau, Nigeria; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US; 4Jos Univ Teaching Hosp, Plateau, Nigeria; 5Harvard-PEPFAR Prgm, Lagos, Nigeria; and 6Johns Hopkins Univ, Baltimore, MD, US
    1032 HBV-specific T Cell Responses in HIV-1/HBV-co-infected Individuals Increase Transiently but Are Not Sustained following 48 Weeks of HBV-active ART
Judy Chang*1, S Sirivichayakul2, A Avihingsanon2, P Thantiworasit2, D Cooper3, G Matthews3, G Dore3, K Ruxrungtham2, and S Lewin1,4,5
1Univ of Melbourne, Australia; 2HIV-NAT and Chulalongkorn Univ, Bangkok, Thailand; 3Natl Ctr in HIV Epi and Clin Res, Univ of New South Wales, Sydney, Australia; 4Alfred Hosp, Melbourne, Australia; and 5Monash Univ, Melbourne, Australia
    1033 Immunopathogenesis of Hepatic Flares after Initiation of ART in HIV/HBV-co-infected Individuals
Megan Crane*1, B Oliver2, G Matthews3, A Avihingsanon4, P Price2,5, K Visvanathan1, M French2,5, G Dore3, K Ruxrungtham4, and S Lewin1,6
1Monash Univ, Melbourne, Australia; 2Univ of Western Australia, Perth; 3Natl Ctr for HIV Epidemiology and Clin Res, Univ of New South Wales, Australia; 4HIV Netherlands Australia Thailand Res Collaboration, Bangkok; 5Royal Perth Hosp, Australia; and 6Alfred Hosp, Melbourne, Australia
    1034 Selection of Lamivudine Resistance Profile Is Constrained by HBV Genotypes in Mono- and HIV-co-infected Patients
Valentina Svicher*1, C Gori2, M Trignetti1, M Visca3, G Cappiello3, M Angelico4, G De Sanctis5, F Ceccherini-Silberstein1, A Spano3, and C F Perno1
1Univ of Tor Vergata, Rome, Italy; 2Natl Inst of Infectious Diseases, L Spallanzani, Rome, Italy; 3San Pertini Hosp, Rome, Italy; 4Univ of Tor Vergata, Rome, Italy; and 5Policlinico “Umberto I”, Rome, Italy
    1035 Identification of HBV Pre-surface and Surface Mutations among HIV+ Individuals with Occult HBV Infection
Christina Martin*, N Shire, S Rouster, T Shata, K Sherman, and J Blackard
Univ of Cincinnati, OH, US
    1036 Long-term Serologic Follow-up of HIV-infected Women with Isolated Hepatitis B Core Antibody: Predictors of Acquisition of Hepatitis B Surface Antibody
Michael Lin*1,2, C Evans3, E Operskalski4, M Augenbraun5, A Howard6, M Young7, L Benning8, M Peters9, A French1,2, and Women's Interagency HIV Study (WIHS)
1Rush Univ Med Ctr, Chicago, IL, US; 2CORE Ctr and Storger Hosp, Chicago, IL, US; 3Univ of Illinois at Chicago, US; 4Univ of Southern California, Los Angeles, US; 5State Univ of NewYork Downstate Med Ctr, Brooklyn, US; 6Montefiore Med Ctr, Bronx, NY, US; 7Georgetown Univ Med Ctr, Washington, DC, US; 8Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; and 9Univ of California, San Francisco, US
    1037 Effect of Nationwide Hepatitis B Vaccination Program on Prevalence of HBV Infection and Factors Associated with Maintaining Protective Anti-HBs Antibody Titers among HIV-infected Persons
H Y Sun1, W C Ko2, H C Lee2, S Y Chang1, and Chien-Chin Hung*1
1Natl Taiwan Univ Coll of Med, Taipei and 2Natl Cheng-Kung Univ Hosp, Taiwan
    1038 Occult Hepatitis B Virus Infection in HIV Patients in an Urban Clinic in Johannesburg, South Africa
Cynthia Firnhaber*1, R Viana2, A Reyneke1, D Schultz1, B Malope1, P Macphail1, I Sanne1, A Di Bisceglie3, and M Kew2
1Univ of the Witwatersrand, Johannesburg, South Africa; 2Univ of the Witwatersrand, Johannesburg, South Africa; and 3Univ of St Louis, MO, US
    1039 Longitudinal Evaluation of Hepatitis B, C, or D Viremia in HIV-HBV-co-infected Patients: Virological Interactions and Effects of Treatment
Anders Boyd*1, K Lacombe1,2,3, P Miailhes4, J Gozlan2,3, P Bonnard5, J M Molina6, C Lascoux-Combe6, L Serfaty3, M Desvarieux1,2,7, and P M Girard2,3
1INSERM UMR S707, Paris, France; 2Univ Pierre and Marie Curie, Paris, France; 3Hosp St Antoine, Paris, France; 4Hosp Hotel Dieu, Hosp Civils de Lyon, France; 5Hosp Tenon, Paris, France; 6Hosp St Louis, Paris, France; and 7Columbia Univ Mailman Sch of Publ Hlth, New York, NY, US
    1040 HBsAg Quantification as Surrogate of Hepatitis Delta Virus Replication in HIV-co-infected Patients
J Martinez-Alarcon1, J Sheldon1,2, Marcelle Bottecchia*1,2, A Madejon2,3, C Toro1, P Rios1,2, J Garcia-Samaniego2,3, and V Soriano1
1Hosp Carlos III, Madrid, Spain; 2Ciber of Liver Diseases, Madrid, Spain; and 3Hosp Carlos III, Madrid, Spain